- Todos > Medicine Information and Evidence for Policy > Medicines Policy
- Todos > Medicine Access and Rational Use > Antimicrobial Drug Resistance
- Todos > Public Health, Innovation, Intellectual Property and Trade > Research and Development (R&D) - Innovation and Financing
- Palabras clave > antibiotic policy
- Palabras clave > antibiotic resistance
- Palabras clave > antimicrobial resistance (AMR)
- Palabras clave > antimicrobials
- Palabras clave > pharmaceutical gaps
- Palabras clave > pharmaceutical industry - incentive for R&D
- Palabras clave > pharmaceutical innovation
- Palabras clave > pharmaceutical research - priorities
- Palabras clave > priority diseases
- Palabras clave > priority medicines
(2010; 224 pages)
High levels of pathogen resistance are, one-by-one, rendering current antibiotics obsolete. Coupled with insufficient investment in discovering new treatments, multidrug-resistant infections pose an increasingly urgent public health concern.
To curb the growth of antibiotic resistance and prevent major morbidity and mortality from multidrug-resistant bacterial infections we must address overuse and actively promote research and development for antibiotics with novel mechanisms of action. This must be done through appropriately designed incentives for health and regulatory systems in addition to economic incentives to attract academic interest and industry investment.
This book analyses many of the proposed policies and incentive mechanisms that are on the table and sheds light on the key issues that can help policy-makers reach informed, concrete decisions on how to avert this potential public health crisis.